GB-AF-005

GB-AF-005 is a preclinical therapeutic candidate being developed by GAT Biosciences for the treatment of macular degeneration. The drug is designed to inhibit or neutralize the activity of Vascular Endothelial Growth Factor (VEGF), a key driver of pathological angiogenesis in retinal diseases. A distinguishing feature of GB-AF-005 is its intended oral route of administration, which aims to provide a less invasive alternative to the current standard-of-care intravitreal injections. While company documentation contains conflicting descriptions regarding its modality—referring to it as both an oral biologic (antibody/inhibitor) and an oral small molecule—it remains a primary candidate in GAT Biosciences' pipeline for chronic ocular disorders.